Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 3
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
MicroRNAs in melanoma development and resistance to target therapy.
Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G. Fattore L, et al. Among authors: ruggiero cf. Oncotarget. 2017 Mar 28;8(13):22262-22278. doi: 10.18632/oncotarget.14763. Oncotarget. 2017. PMID: 28118616 Free PMC article. Review.
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Theranostics. 2022 Oct 24;12(17):7420-7430. doi: 10.7150/thno.77761. eCollection 2022. Theranostics. 2022. PMID: 36438490 Free PMC article.
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.
Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA, Mancini R, Ciliberto G. Fattore L, et al. Among authors: ruggiero cf. Cell Death Differ. 2019 Jul;26(7):1267-1282. doi: 10.1038/s41418-018-0205-5. Epub 2018 Sep 25. Cell Death Differ. 2019. PMID: 30254376 Free PMC article.
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L, Campani V, Ruggiero CF, Salvati V, Liguoro D, Scotti L, Botti G, Ascierto PA, Mancini R, De Rosa G, Ciliberto G. Fattore L, et al. Among authors: ruggiero cf. Int J Mol Sci. 2020 Mar 12;21(6):1930. doi: 10.3390/ijms21061930. Int J Mol Sci. 2020. PMID: 32178301 Free PMC article.
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.
Ruggiero CF, Malpicci D, Fattore L, Madonna G, Vanella V, Mallardo D, Liguoro D, Salvati V, Capone M, Bedogni B, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Cancers (Basel). 2019 Sep 25;11(10):1425. doi: 10.3390/cancers11101425. Cancers (Basel). 2019. PMID: 31557826 Free PMC article.